Mip3a/relMtb
Candidate Overview
The Mip3a/relMtb vaccine is an intranasal therapeutic DNA fusion vaccine encoding the M. tuberculosis stringent response antigen relMtb (Rv2583c) linked to the immature dendritic cell–targeting chemokine Mip3a/CCL20, formulated as a plasmid DNA construct without an added adjuvant.
Sponsor / Lead Developer: Johns Hopkins University
Primary Indication: Immunotherapy / Shortening TB treatment
Other Indication(s): Immunotherapy/Improving TB Cure Rates
Target Population(s): Adults and People with active TB
Target Route of Administration: Intranasal
Immune tissue localization: Blood, Lung, Lymph node, and Spleen
Immunological responses: T-cell
Preclinical Animal Models: Mouse and Nonhuman primate
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Preferential immune tissue localization | Lung Lymph node Spleen Blood (PBMCs) Bronchoalveolar lavage |
|
| Trained immunity | No | |